← Leaderboards
Tobias Schatton
Brigham And Women'S Hospital
$4,457,299
Attributed
$6,871,451
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,871,451 · 3
By mechanism
R01$6,871,451 · 3
Top collaborators
- Steven Russell Barthel9 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- John P Forman$11,830,902
- Francis W. Luscinskas$14,265,022
- Vijay K Kuchroo$71,617,613
- Charles J Dimitroff$9,730,798
- Tanya N. Mayadas$28,624,599
Others in their field
Other Emerging Leaders on “Antibodies”
- Bambra Strokes · Ppd Development Lp$461,655,950
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$169,304,044
- Yunda Huang · Fred Hutchinson Cancer Center$73,421,550
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Hanjoon Ryu$28,519,898
- Wendy Sammons-Jackson · National Institute Of Allergy And Infectious Diseases$27,369,420
Research focus
AntibodiesGrowthTumorigenesisVariantTissuesNeoplasm MetastasisMelanoma CellMelanomaTumorTreatment EfficacyT-LymphocyteNeoplastic CellPathway InteractionsCancer CellImmuneMediatingCellsLigandsKnockout MiceResearch Project GrantsInsightTumor ProgressionMouse ModelTherapeutic Target
Grant awards (16)
Cell type-directed Tim-3 targeting in melanoma$580,109
R01 · FY2025 · CA
Functional analysis of a novelintegrin-dependent metastasis pathway in melanoma$511,820
R01 · FY2025 · CA · contact PI
Cell type-directed Tim-3 targeting in melanoma$551,025
R01 · FY2024 · CA
Functional analysis of a novelintegrin-dependent metastasis pathway in melanoma$486,230
R01 · FY2024 · CA · contact PI
Cell type-directed Tim-3 targeting in melanoma$572,297
R01 · FY2023 · CA
Functional analysis of a novelintegrin-dependent metastasis pathway in melanoma$501,583
R01 · FY2023 · CA · contact PI
Cell type-directed Tim-3 targeting in melanoma$592,227
R01 · FY2022 · CA
Functional analysis of a novelintegrin-dependent metastasis pathway in melanoma$508,408
R01 · FY2022 · CA · contact PI
Functional analysis of a novelintegrin-dependent metastasis pathway in melanoma$524,606
R01 · FY2021 · CA · contact PI
Role of melanoma-PD-1 in cancer progression$395,502
R01 · FY2021 · CA · contact PI
Role of melanoma-PD-1 in cancer progression$395,502
R01 · FY2020 · CA · contact PI
Role of melanoma-PD-1 in cancer progression$383,636
R01 · FY2019 · CA · contact PI
Role of melanoma-PD-1 in cancer progression$5,903
R01 · FY2019 · CA · contact PI
Role of melanoma-PD-1 in cancer progression$395,501
R01 · FY2018 · CA · contact PI
Role of melanoma-PD-1 in cancer progression: diversity supplement$71,600
R01 · FY2018 · CA · contact PI
Role of melanoma-PD-1 in cancer progression$395,502
R01 · FY2017 · CA · contact PI